InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
InflaRx (Nasdaq: IFRX) will participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston, MA from November 10–12, 2025. The company will appear in a fireside chat on November 11 at 2:30 PM ET and will hold one-on-one investor meetings the same day. A live stream and replay link for the fireside chat will be provided.
InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics that target the complement system, developing vilobelimab (intravenous anti-C5a antibody) and INF904 (oral C5a receptor inhibitor). The company has offices in Jena and Munich, Germany, and Ann Arbor, MI.
InflaRx (Nasdaq: IFRX) parteciperà alla Guggenheim Securities 2nd Annual Healthcare Innovation Conference a Boston, MA dal 10 al 12 novembre 2025. L'azienda interverrà in una chiacchierata informale (fireside chat) il 11 novembre alle ore 14:30 ET e terrà incontri individuali con gli investitori nello stesso giorno. Verrà fornito un link per lo streaming live e per la replica della chiacchierata informale.
InflaRx è una società biofarmaceutica focalizzata su terapie anti-infiammatorie che mirano al sistema complemento, sviluppando vilobelimab (anticorpo anti-C5a somministrato per via endovenosa) e INF904 (inibitore orale del recettore C5a). L'azienda ha uffici a Jena e Monaco di Baviera, in Germania, e ad Ann Arbor, MI.
InflaRx (Nasdaq: IFRX) participará en la 2ª Conferencia Anual de Innovación en Salud de Guggenheim Securities en Boston, MA, del 10 al 12 de noviembre de 2025. La empresa participará en una charla junto a la chimenea (fireside chat) el 11 de noviembre a las 2:30 PM ET y mantendrá reuniones con inversores one‑on‑one el mismo día. Se proporcionará un enlace en vivo y una regrabación de la charla junto a la chimenea.
InflaRx es una empresa biofarmacéutica centrada en terapias antiinflamatorias que apuntan al sistema complemento, desarrollando vilobelimab (anticuerpo anti-C5a administrado por vía intravenosa) e INF904 (inhibidor oral del receptor C5a). La empresa tiene oficinas en Jena y Múnich, Alemania, y Ann Arbor, MI.
InflaRx (나스닥: IFRX)은 매사추세츠주 보스턴에서 열리는 Guggenheim Securities의 2nd Annual Healthcare Innovation Conference에 2025년 11월 10일부터 12일까지 참가합니다. 회사는 11월 11일 동부 표준시 2:30 PM에 fireside chat에 참여하고 같은 날 1대1 투자자 회의를 가질 예정입니다. fireside chat의 라이브 스트림 및 재생 링크가 제공될 예정입니다.
InflaRx는 보체 시스템을 표적으로 하는 항염증 치료제를 개발하는 생물의약 회사로, 정맥 주사로 투여되는 anti-C5a 항체인 vilobelimab와 경구 C5a 수용체 억제제 INF904를 개발하고 있습니다. 이 회사의 본사는 독일 야니아(Jena)와 뮌헨(Munich), 독립은 Ann Arbor, Michigan에 위치해 있습니다.
InflaRx ( Nasdaq : IFRX ) participera à la 2e Conférence annuelle Guggenheim Securities sur l'innovation en soins de santé à Boston, MA du 10 au 12 novembre 2025. L'entreprise interviendra lors d'une conversation au coin du feu le 11 novembre à 14h30 ET et tiendra des réunions investisseurs en tête-à-tête le même jour. Un lien de diffusion en direct et une ré-vision de la discussion seront fournis.
InflaRx est une société biopharmaceutique axée sur les thérapies anti-inflammatoires ciblant le système du complément, développant vilobelimab (anticorps anti-C5a administré par voie intraveineuse) et INF904 (inhibiteur oral du récepteur C5a). La société dispose de bureaux à Jena et à Munich, en Allemagne, et à Ann Arbor, MI.
InflaRx (Nasdaq: IFRX) wird an der Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston, MA vom 10. bis 12. November 2025 teilnehmen. Das Unternehmen wird an einem Fireside-Chat am 11. November um 14:30 Uhr ET teilnehmen und am selben Tag One-on-One-Investorengespräche führen. Ein Live-Stream- und Replay-Link für das Fireside-Chat wird bereitgestellt.
InflaRx ist ein biopharmazeutisches Unternehmen, das sich auf entzündungshemmende Therapeutika konzentriert, die das Komplementsystem anvisieren, und entwickelt Vilobelimab (intravenöses Anti-C5a-Antikörper) und INF904 (oraler C5a-Rezeptor-Inhibitor). Das Unternehmen hat Niederlassungen in Jena und München, Deutschland, sowie in Ann Arbor, MI.
InflaRx (ناسداك: IFRX) ستشارك في مؤتمر Guggenheim Securities السنوي الثاني لابتكار الرعاية الصحية في بوسطن، ماساتشوستس من 10 إلى 12 نوفمبر 2025. ستظهر الشركة في محادثة بجوار المدفأة في 11 نوفمبر الساعة 2:30 مساءً بتوقيت شرق الولايات المتحدة وستعقد اجتماعات مع المستثمرين وجهاً لوجه في اليوم نفسه. سيتم توفير رابط مباشر للبث وربط إعادة العرض للمحادثة بجوار المدفأة.
InflaRx هي شركة أدوية حيوية تركز على العلاجات المضادة للالتهابات المستهدفة لنظام المكمل، وتطور vilobelimab (جسم مضاد لـ C5a يُعطى وريدياً) و INF904 (مثبط مستقبل C5a فموي). لدى الشركة مكاتب في جينا وميونيخ في ألمانيا، وفي آن أربور، مي.
InflaRx (纳斯达克：IFRX) 将参加在马萨诸塞州波士顿举行的 Guggenheim Securities 第2届年度医疗保健创新大会，时间为 2025年11月10–12日。公司将于 11月11日美国东部时间下午2:30进行炉边谈话（fireside chat），同日还将进行一对一投资者会面。将提供炉边谈话的直播链接及回放链接。
InflaRx 是一家专注于靶向补体系统的抗炎治疗药物的生物制药公司，开发 vilobelimab（静脉注射的抗C5a抗体）和 INF904（口服的 C5a 受体抑制剂）。公司在德国的耶拿（Jena）和慕尼黑（Munich）设有办事处，在美国密歇根州安娜堡（Ann Arbor, MI）设有办事处。
- None.
- None.
JENA, Germany, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference. Details are as follows:
Guggenheim Securities 2nd Annual Healthcare Innovation Conference
November 10 - 12, 2025 in Boston, MA
Fireside chat on November 11 at 2:30 PM ET
InflaRx will also conduct one-on-one investor meetings on November 11th. A link to view the fireside chat live stream and its replay is available here.
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies. InflaRx is also developing INF904, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor.
InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, “Risk factors” and “Cautionary statement regarding forward looking statements”, in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
FAQ
When will InflaRx (IFRX) present at the Guggenheim Healthcare Innovation Conference in 2025?
How can investors watch the InflaRx (IFRX) fireside chat on November 11, 2025?
Will InflaRx (IFRX) meet with investors at the Guggenheim conference?
What topics will InflaRx (IFRX) likely cover at the Guggenheim fireside chat?
Where is the Guggenheim Securities 2nd Annual Healthcare Innovation Conference taking place for InflaRx (IFRX)?
Who should investors contact for InflaRx (IFRX) investor relations ahead of the November 2025 conference?
